arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Prime Medicine, Inc.

PRME

$3.08 ▲ +0.15 (+5.13%) at close

23 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Prime Medicine, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $545.5M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -52.2% ↘

FCF / Share $-0.24

Trailing P/E —

Price / Book 7.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$838.00K

↓ -61.6% —

Net Income Profit after all expenses

$-49.12M

↑ +5.3% —

FCF / Share Free cash flow per share

$-0.24

↑ +38.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	-61.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-870%)	486.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5977%)	—	146.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1725%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	30.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	22.6% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	27.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	10.9% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	9.1% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	56.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	20.0% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	2.1% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	65.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	73.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	72.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-5.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	5.3% Fair ↑ Fair Improving Year-over-year change in net income	-9.0% Weak ↑ Weak Improving Year-over-year change in net income	-13.4% Weak ↓ Weak Declining Year-over-year change in net income	-13.4% Weak ↓ Weak Declining Year-over-year change in net income	-13.4% Weak ↓ Weak Declining Year-over-year change in net income	35.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-16.2% Weak ↑ Weak Improving Year-over-year change in net income	-16.2% Weak ↑ Weak Improving Year-over-year change in net income	-16.2% Weak ↑ Weak Improving Year-over-year change in net income	-67.1% Weak → Weak Stable Year-over-year change in net income	-65.3% Weak ↓ Weak Declining Year-over-year change in net income	-65.3% Weak ↓ Weak Declining Year-over-year change in net income	-65.3% Weak ↓ Weak Declining Year-over-year change in net income	37.6% Excellent Excellent Year-over-year change in net income	72.5% Excellent Excellent Year-over-year change in net income	—	—	—	—	—	—	—	—
FCF Growth YoY (%)	38.1% Excellent Excellent Year-over-year change in free cash flow	—	—	—	41.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-37.1% Weak Weak Year-over-year change in free cash flow	—	—	—	82.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	-0.34x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.53x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.70x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.11x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.05x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	2.20x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.22x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-52.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-26.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-69.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-15.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	11.2% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	10.7% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	9.4% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	30.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	8.7% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-17.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-14.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-21.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-35.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-10.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-14.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-19.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-64.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-527%)	-38.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-354%)	-32.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-314%)	-85.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-668%)	-48.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-424%)	-27.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-284%)	-24.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-23.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-255%)	-18.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-225%)	-49.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-429%)	-20.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	-16.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	-14.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-194%)	-12.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	10.7% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-29%)	12.2% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-19%)	14.3% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	40.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+168%)	91.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+512%)	—	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-64.11M	$-63.03M	$-71.40M	$-53.80M	$-91.88M	$-182.48M	$-117.98M	$-55.60M	$-94.16M	$-41.57M	$-43.96M	$-120.58M	$-133.46M	$-187.62M	$-47.95M	$-92.24M	$-164.25M	$-185.42M	$-200.66M	—	—	$-36.98M	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	$0.01	$0.01	$0.01	—	$0.00	$0.00	$0.01	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.28	$-0.24	$-0.32	$-0.41	$-0.40	$-0.31	$-0.44	$-0.46	$-0.44	$-0.72	$-0.55	$-0.47	$-0.44	$0.72	$-1.61	$-1.76	$-1.58	$-4.45	$-1.52	—	—	—	—
Free Cash Flow per Share (USD)	$-0.24	—	$-0.22	$-0.33	$-0.39	—	—	—	$-0.67	—	—	—	$-0.49	—	—	$-1.24	$-2.75	—	—	—	—	—	—
Book Value per Share (USD)	$0.42	$0.67	$0.90	$0.45	$0.82	$1.17	$1.44	$1.64	$2.03	$1.37	$1.99	$2.47	$2.87	$3.25	$-6.65	$-9.64	$-8.76	$-4.82	$-6.31	—	—	—	—
Tangible Book Value per Share (USD)	$0.42	$0.67	$0.90	$0.45	$0.82	$1.17	$1.44	$1.64	$2.03	$1.37	$1.99	$2.47	$2.87	$3.25	$-6.65	$-9.64	$-8.76	$-4.82	$-6.31	—	—	—	—
Basic Weighted Avg Shares (shares)	177.10M	—	160.50M	129.19M	130.88M	—	119.76M	119.19M	104.47M	—	91.85M	90.47M	89.06M	—	22.23M	20.23M	19.05M	—	14.97M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$101.60M	$143.84M	$196.39M	$87.18M	$129.48M	$173.93M	$208.19M	$150.05M	$193.21M	$86.55M	$145.16M	$189.77M	$229.63M	$269.90M	$126.63M	—	—	$212.60M	—	—	—	—	—
Total Equity (USD)	$76.70M	$120.87M	$161.82M	$60.86M	$106.92M	$153.15M	$189.50M	$196.59M	$243.77M	$133.07M	$193.96M	$240.10M	$278.80M	$316.27M	$-223.10M	$-195.06M	$-166.94M	$-156.24M	$-94.42M	$-78.37M	$2.34M	$2.34M	$-2.60M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	$838.00K	$1.23M	$1.11M	$1.45M	$2.18M	$209.00K	$0.00	$591.00K	$0.00	—	—	—	—	—	—	—	—	—	—	—	—	—
Depreciation Expense (USD)	$1.86M	$1.88M	$1.88M	$1.86M	$1.70M	$1.72M	$1.56M	$1.54M	$1.31M	$1.25M	$1.24M	$1.12M	$1.05M	$870.00K	$600.00K	$430.00K	$293.00K	$229.00K	$200.00K	—	—	—	—
Net Income, GAAP (USD)	$-49.12M	$-46.08M	$-51.89M	$-51.89M	$-51.89M	$-42.28M	$-45.76M	$-45.76M	$-45.76M	$-65.64M	$-39.40M	$-39.40M	$-39.40M	$-39.28M	$-23.84M	$-23.84M	$-23.84M	$-62.91M	$-86.66M	—	—	—	—
Operating Cash Flow (USD)	$-42.71M	$-37.26M	$-35.04M	$-41.41M	$-48.86M	$16.25M	—	—	$-67.71M	$-43.86M	—	—	$-41.56M	$-30.71M	—	$-20.22M	$-50.79M	$-13.19M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters

Prime Medicine, Inc.

Analytical Summary

23-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PRME with peers